Header links
Intranet
Donate now
image/svg+xml Map
Contact us

Olga Simó Servat

Olga Simó Servat

Institutions of which they are part

Main researcher
Diabetes and Metabolism
Vall Hebron Institut de Recerca
Olga Simó Servat

Olga Simó Servat

Olga Simó Servat

Institutions of which they are part

Main researcher
Diabetes and Metabolism
Vall Hebron Institut de Recerca

Projects

Neuroprotección mediada por GLP-1: desarrollo preclínico de una nueva estrategia terapéutica para la retinopatía diabética

IP: Cristina Hernández Pascual
Collaborators: Olga Simó Servat
Funding agency: Instituto de Salud Carlos III
Funding: 101277
Reference: PI13/00603
Duration: 01/01/2014 - 31/12/2016

Preventing cardiovascular ischemic events and arresting their consequences in type 2 diabetic population: a multidisciplinary clinical and experimental approach

IP: -
Collaborators: Ignacio Ferreira González, José Antonio Barrabés Riu, Joan Montaner Villalonga, Immaculada Raurell Saborit, Joan López Hellin, Antonio González Fernández, Antonia Sambola Ayala, Joaquin Lopez Soriano, Preventing cardiovascular ischemic events and arresting their consequences in type 2 diabetic population: a multidisciplinary c, Antonio Rodríguez Sinovas, Rafael Simó Canonge, Francesc Moreso Mateos, Cristina Hernández Pascual, Anna Penalba Morenilla, Preventing cardiovascular ischemic events and arresting their consequences in type 2 diabetic population: a multidisciplinary c, Neus Bellera Gotarda, Natalia Ramos Terrades, Andreea Ciudin Mihai, Maria Mar Hernandez Guillamon, Meritxell Ibernon Vilaró, Ignasi Barba Vert, Jordi Bañeras Rius, Bruno García del Blanco, Daniel Serón Micas, María Eugenia Espinel Garuz, Marisol Ruiz Meana, Maria Pilar Delgado Martínez, Irina Betsabe Torres Rodriguez, Javier Inserte Igual, Anna Rosell Novel, Olga Simó Servat, Joan Genescà Ferrer, Mònica Pons Delgado, M Antonieta Azancot Rivero, Maria Nazarena Pizzi, M Antonieta Azancot Rivero
Funding agency: Instituto de Salud Carlos III
Funding: 825000
Reference: PIE13/00027
Duration: 01/01/2014 - 30/06/2018

Related news

Dra. Andreea Ciudin

A new guideline proposes a change in the pharmacological approach to obesity

The work represents a paradigm shift in the clinical approach to this chronic, multifactorial disease, based on the clinical context of each patient and not only on weight loss.

Dra. Andreea Ciudin, Marta Comas i Juan José Cortés

A new oral drug for obesity shows positive results in an international study

The results of a phase 3 clinical trial show that orforglipron reduces body weight by an average of 11% and improves cardiovascular risk factors.

Equip del grup de Diabetis i Metabolisme del VHIR

Fundaluce supports research into a new therapeutic strategy for retinitis pigmentosa

Dr. Maria Llorián-Salvador, from the Diabetes and Metabolism Research Group at VHIR, is leading this project to identify new therapies for this inherited disease that causes progressive vision loss.

See more

Related professionals

Ana Lain Fernandez

Ana Lain Fernandez

Bioengineering, Cell Therapy and Surgery in Congenital Malformations
Read more
Eduardo Fidel Tizzano

Eduardo Fidel Tizzano

Head of group
Genetics Medicine
Read more
Jose Maria Zuazo Morquecho

Jose Maria Zuazo Morquecho

Liver Diseases
Read more
Laura Ludovica Gramegna .

Laura Ludovica Gramegna .

Research technician
Stroke research
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.